CDC has reported that hepatitis C kills more Americans than sixty other notifiable infectious diseases combined, and it still contributes to over 11,000 deaths a year, even though it can be cured. Even now, over a decade after curative treatments have been available, CDC found that only one in three people with evidence of infection had been cured, and the number of US adults estimated to be living with HCV was 2.5 to 4 million in 2017-2020, a prevalence unchanged from 2013-2016. Many of the easiest people to reach, those in primary care and traditional health care settings, have already accessed curative treatment. We urge CMS to issue this NCD without setting restrictions so that as many Medicare beneficiaries as possible can access these curative treatments.
Comments to the Oregon PDAB on PBM Practices and Continuity of Care
We strongly support the Board’s recommendation to strengthen PBM oversight through standardized financial reporting, disclosure of affiliated businesses, independent audit authority, and greater public transparency. PBMs play a significant role in determining which medications patients can access and how much they pay at the pharmacy counter. Yet complex financial arrangements make it difficult to determine whether negotiated rebates and discounts ultimately benefit patients.
Comments to Senate Finance Comm. Democrats on private health coverage reform
As Congress considers reforms to private health insurance, we urge you to ensure that coverage provides meaningful access to the medications, services, and care patients need and protects them from practices that shift costs or create unnecessary barriers to treatment.
Comments urging the Pharmacy Quality Alliance to develop a new PrEP adherence measure
We submitted comments to Pharmacy Quality Alliance supporting a timely replacement of the ARV treatment adherence measure and urging a new PrEP adherence measure, with both measures designed to account for #insurer-imposed disruptions in HIV care.
Comments to CMS on Quality Measures and ADAP 340B Calculation in the CY2027 Physician Fee Schedule
We support the adoption of stronger quality measures for HIV and viral hepatitis, including screening and treatment for hepatitis B and C, as well as a more accurate ADAP 340B calculation for the Medicare drug inflation rebate. Federal & state quality measures help ensure that health systems prioritize these key interventions.